Company Profile
Viatris Inc. Stock Price, News & Catalysts
- Ticker:
- VTRS
- Exchange:
- NASDAQ
- Sector:
- Generics, Small Molecule Drugs
- Location:
- United States
Stock performance
17.46 USD (-1.47%)
Close
Last updated: October 1, 2026
18.3B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, VTRS closed down 1.47% at $17.46. No new same-company headline was identified in the current news window.
Company overview
Global Medicines Company
Viatris is a global healthcare company that develops, manufactures, and commercializes branded medicines, generic drugs, complex products, and biosimilars. Its portfolio is distributed across developed and emerging markets through a broad manufacturing, regulatory, and commercial network.
Established Brands Portfolio
The company's established brands include medicines used in cardiovascular disease, central nervous system disorders, respiratory disease, infectious disease, and other chronic conditions. These products often rely on geographic expansion, lifecycle management, and durable physician familiarity rather than exclusively on new molecular innovation.
Generics and Complex Products
Viatris manufactures oral solids, injectables, transdermal products, respiratory medicines, and other technically complex dosage forms. Scale in development, manufacturing, and regulatory submissions allows the company to supply a wide range of affordable medicines across multiple regions.
Biosimilars Business
The biosimilars portfolio gives Viatris exposure to large biologic markets through products referencing established therapies in oncology, immunology, diabetes, and other specialties. Commercialization is frequently conducted through regional partnerships that divide development, manufacturing, and market responsibilities.
Pipeline and Portfolio Management
Viatris combines internal development with licensing, partnerships, acquisitions, and divestitures to reshape its portfolio. New products include Gwyn Lo, while MR-107A-02 is being developed as a fast-acting, non-opioid meloxicam formulation for moderate-to-severe acute pain.
Future catalysts
- Commercial availability of Gwyn Lo later in 2026.
- FDA PDUFA decision for MR-107A-02 in moderate-to-severe acute pain on December 27, 2026.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Viatris Inc. (VTRS)?
Viatris Inc. (VTRS) most recently closed at 17.46 USD, a -1.47% move versus the previous session.
What is the market cap of Viatris Inc. (VTRS)?
Viatris Inc. currently has a market capitalization of 18.3B USD on BioPharmSignal.
What does Viatris Inc. do?
Global Medicines Company Viatris is a global healthcare company that develops, manufactures, and commercializes branded medicines, generic drugs, complex products, and biosimilars. Its portfolio is distributed across developed and emerging markets through a broad manufacturing, regulatory, and commercial network. Established Brands Portfolio The company's...
On which exchange is VTRS stock listed?
Viatris Inc. (VTRS) is associated with NASDAQ, United States, Generics, Small Molecule Drugs.
What is MR-107A-02?
FDA PDUFA decision for MR-107A-02 in moderate-to-severe acute pain on December 27, 2026.
Which conditions is Viatris Inc. targeting with MR-107A-02?
Viatris Inc. is associated with oncology, immunology, cardiovascular disease based on its company overview and current catalyst commentary.
How does Viatris Inc. describe recent progress with MR-107A-02?
FDA PDUFA decision for MR-107A-02 in moderate-to-severe acute pain on December 27, 2026.
What is Global?
Global Medicines Company Viatris is a global healthcare company that develops, manufactures, and commercializes branded medicines, generic drugs, complex products, and biosimilars.